-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
Zipalertinib Meets Primary Endpoint in Phase 2b Trial
The drug’s developers have said the data show a positive overall response rate in previously treated patients with NSCLC with EGFR exon 20 insertion mutations.
-
Climate Change-Fueled Natural Disasters and the Impacts on Lung Cancer Care
In our continuing series on role the environment plays in thoracic oncology, Dr. Roselle De Guzman outlines the risks posed by our changing climate and the potential benefits of taking a proactive approach to reduce those risks.
-
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents?
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.
-
Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care.
-
Updated Data Show Median OS of 16.9 months in Patients with Advanced NSCLC Treated with THIO
Though the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent.
-
US FDA Grants Priority Review for Zongertinib for Advanced HER2+ NSCLC
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients.
-
Healthcare Community Can Still Take Action to Combat Effects of Climate Change
Dr. Leticia Nogueira says the time has come for the lung cancer community to champion environmentally responsible practices that help mitigate cancer risks and outcomes.
-
Where There’s Smoke: The Global Threat of Lung Cancer in Patients with No Smoking History and its Implications in Screening
Dr. Lucia Viola says that access to genomic profiling is crucial for gathering information about patients who do not smoke.
-
Study Finds Correlations Between Certain Factors, Rates of Nodal Upstaging
Dr. Stella Martinez recently shared the latest data and explored the challenges and opportunities in lung cancer surgery in Latin America.
-
Palliative Care: A Path to Living Well with Advanced Cancer
Patient Advocates Angus Pratt and Terri Ann DiJulio explore the key role that the medical community plays in helping patients and families understand the importance of palliative care.